MARÍA DEL ROCÍO
HERRERO VANRELL
Catedrática de universidad
MIRIAM ANA
GONZÁLEZ-CELA CASAMAYOR
Investigadora en el periodo 2019-2023
Publicaciones en las que colabora con MIRIAM ANA GONZÁLEZ-CELA CASAMAYOR (11)
2024
-
Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents
Drug Delivery and Translational Research, Vol. 14, Núm. 10, pp. 2804-2822
-
Topical Insulin Eye Drops: Stability and Safety of Two Compounded Formulations for Treating Persistent Corneal Epithelial Defects
Pharmaceutics, Vol. 16, Núm. 5
2023
-
A novel osmoprotective liposomal formulation from synthetic phospholipids to reduce in vitro hyperosmolar stress in dry eye treatments
Journal of Liposome Research, Vol. 33, Núm. 2, pp. 117-128
-
Desarrollo de una formulación antiglaucomatosa tópica a partir de una lágrima artificial
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
Long-acting hybrid microemulsion for the simultaneous treatment of glaucoma and ocular surface diseases
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
New trends towards glaucoma treatment: Topical osmoprotective microemulsions loaded with latanoprost
Ocular Surface, Vol. 29, pp. 314-330
2022
-
Development of an osmoprotective microemulsion as a therapeutic platform for ocular surface protection
International Journal of Pharmaceutics, Vol. 623
-
Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment
Pharmaceutics, Vol. 14, Núm. 7
2021
-
Combined hyperosmolarity and inflammatory conditions in stressed human corneal epithelial cells and macrophages to evaluate osmoprotective agents as potential DED treatments
Experimental Eye Research, Vol. 211
-
Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection
Expert Opinion on Drug Delivery, Vol. 18, Núm. 7, pp. 819-847
-
“In vitro” hyperosmolar design in human corneal epithelial cells and inflammation in macrophages: avoiding the use of animals in the screening of ocular surface therapies
RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 41-43